229 related articles for article (PubMed ID: 34728134)
1. Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine.
Sud A; Salamanca-Buentello F; Buchman DZ; Sabioni P; Majid U
J Subst Abuse Treat; 2022 Apr; 135():108651. PubMed ID: 34728134
[TBL] [Abstract][Full Text] [Related]
2. Bridging the Macro-micro Divide: A Qualitative Meta-synthesis on the Perspectives and Experiences of Health Care Providers on the Extramedical Use and Diversion of Buprenorphine.
Kankanam Gamage K; Tejpar S; Majid U; Dixon K; Sabioni P; Sud A
J Addict Med; 2023 Jan-Feb 01; 17(1):e1-e10. PubMed ID: 35914107
[TBL] [Abstract][Full Text] [Related]
3. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
4. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
6. A mixed-methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community-based care in England and Wales.
Gibson R; MacLeod N; Donaldson LJ; Williams H; Hibbert P; Parry G; Bhatt J; Sheikh A; Carson-Stevens A
Addiction; 2020 Nov; 115(11):2066-2076. PubMed ID: 32149443
[TBL] [Abstract][Full Text] [Related]
7. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
8. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Johnson B; Monwell B; Capusan AJ
Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
[TBL] [Abstract][Full Text] [Related]
9. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
10. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
[TBL] [Abstract][Full Text] [Related]
11. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
12. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
13. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
14. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
15. Long-acting depot buprenorphine in people who are homeless: Views and experiences.
Matheson C; Foster R; Schofield J; Browne T
J Subst Abuse Treat; 2022 Aug; 139():108781. PubMed ID: 35450752
[TBL] [Abstract][Full Text] [Related]
16. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
[TBL] [Abstract][Full Text] [Related]
17. "
Checkley L; Steiger S; Knight KR
Subst Abus; 2022; 43(1):767-773. PubMed ID: 35112998
[No Abstract] [Full Text] [Related]
18. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.
Johnson B; Richert T
J Addict Dis; 2015; 34(1):1-17. PubMed ID: 25496247
[TBL] [Abstract][Full Text] [Related]
19. "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
Hayes BT; Jakubowski A; Fitzsimmons C; Garcia B; Ramirez F; Fox AD
Subst Use Misuse; 2021; 56(8):1137-1143. PubMed ID: 33939937
[TBL] [Abstract][Full Text] [Related]
20. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.
Leece P; Khorasheh T; Corace K; Strike C; Bayoumi AM; Taha S; Marks E; Pach B; Ahamad K; Grennell E; Holowaty M; Manson H; Straus SE
BMJ Open; 2019 Dec; 9(12):e032285. PubMed ID: 31843837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
